Background: We and others have demonstrated that adoptive cell therapy with Epstein-Barr virus (EBV)-specific autologous cytotoxic T lymphocytes (CTLs) may control disease progression in patients with EBV-associated nasopharyngeal carcinoma (NPC). With the aim of favoring in vivo T-cell expansion, we optimized our cell therapy approach by administering higher doses of EBV-specific CTLs, following lymphodepleting chemotherapy.Patients and methods: Eleven patients with EBV-related NPC in whom conventional treatment failed have been enrolled. Patients received nonmyeloablative lymphodepleting chemotherapy consisting of cyclophosphamide and fludarabine. Two doses of autologous EBV-specific CTLs were subsequently infused, 2 weeks apart. Study end points were feasibility and clinical outcome.Results: All patients enrolled completed the treatment and were assessable for analysis. The median dose of CTLs per infusion was 3.7 x 10(8). Therapy was well tolerated, with no severe adverse events ascribable to either chemotherapy or cell therapy. Disease control (defined as either tumor regression or disease stabilization lasting >4 months) was obtained in 6 of 11 patients, in keeping with previously published results.Conclusions: Our data confirm that EBV-specific CTL therapy is safe and associated with antitumor activity in patients with advanced NPC. The use of lymphodepleting chemotherapy before high-dose CTL infusion did not enhance the clinical benefit observed in our previous series.

Secondino, S., Zecca, M., Licitra, L., Gurrado, A., Schiavetto, I., Bossi, P., Locati, L., Schiavo, R., Basso, S., Baldanti, F., Maccario, R., Locatelli, F., Siena, S., Pedrazzoli, P., Comoli, P., T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results, <<ANNALS OF ONCOLOGY>>, 2012; 23 (2): 435-441. [doi:10.1093/annonc/mdr134] [https://hdl.handle.net/10807/245760]

T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results

Locatelli, Franco;
2012

Abstract

Background: We and others have demonstrated that adoptive cell therapy with Epstein-Barr virus (EBV)-specific autologous cytotoxic T lymphocytes (CTLs) may control disease progression in patients with EBV-associated nasopharyngeal carcinoma (NPC). With the aim of favoring in vivo T-cell expansion, we optimized our cell therapy approach by administering higher doses of EBV-specific CTLs, following lymphodepleting chemotherapy.Patients and methods: Eleven patients with EBV-related NPC in whom conventional treatment failed have been enrolled. Patients received nonmyeloablative lymphodepleting chemotherapy consisting of cyclophosphamide and fludarabine. Two doses of autologous EBV-specific CTLs were subsequently infused, 2 weeks apart. Study end points were feasibility and clinical outcome.Results: All patients enrolled completed the treatment and were assessable for analysis. The median dose of CTLs per infusion was 3.7 x 10(8). Therapy was well tolerated, with no severe adverse events ascribable to either chemotherapy or cell therapy. Disease control (defined as either tumor regression or disease stabilization lasting >4 months) was obtained in 6 of 11 patients, in keeping with previously published results.Conclusions: Our data confirm that EBV-specific CTL therapy is safe and associated with antitumor activity in patients with advanced NPC. The use of lymphodepleting chemotherapy before high-dose CTL infusion did not enhance the clinical benefit observed in our previous series.
2012
Inglese
Secondino, S., Zecca, M., Licitra, L., Gurrado, A., Schiavetto, I., Bossi, P., Locati, L., Schiavo, R., Basso, S., Baldanti, F., Maccario, R., Locatelli, F., Siena, S., Pedrazzoli, P., Comoli, P., T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results, <<ANNALS OF ONCOLOGY>>, 2012; 23 (2): 435-441. [doi:10.1093/annonc/mdr134] [https://hdl.handle.net/10807/245760]
File in questo prodotto:
File Dimensione Formato  
t-cell therapy.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Note: https://www.elsevier.com/about/policies/open-access-licenses/elsevier-user-license
Licenza: Copyright dell'editore
Dimensione 269.17 kB
Formato Adobe PDF
269.17 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/245760
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 48
social impact